Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$76,725.00-1.96%ETH$2,250.28-1.00%GOLD$3,956.50-0.33%OIL$96.30-0.17%
Smart Investors Daily
SID Premium
ST

NASDAQ · STTK

Shattuck Labs, Inc.

Healthcare · Biotechnology

$5.56

Down-$0.24 (-4.32%)

Updated Nov 2, 2026, 11:57 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
154.73M
P/E ratio
-4.25
Dividend yield
0.00%
52-week range
$1.72 – $8.33
Volume
951.48K
Avg. volume
297.21K

Price performance · STTK

STTK price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

STTK closed at $5.56 after 20 trading sessions, down 14.46% for the selected period.

Last close
$5.56
Period change
-14.46%
Period low
$5.33
Period high
$6.50
Daily close
View OHLC price history
STTK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$5.67$5.74$5.36$5.56951.48K
Oct 29, 2026$5.85$5.95$5.57$5.72676.33K
Oct 28, 2026$5.72$5.94$5.62$5.805799.28K
Oct 27, 2026$5.55$5.82$5.48$5.77699.95K
Oct 26, 2026$5.53$5.69$5.46$5.54706.1K
Oct 23, 2026$5.54$5.595$5.36$5.49700.5K
Oct 22, 2026$5.56$5.715$5.43$5.601.22M
Oct 21, 2026$5.85$6.00$5.57$5.581.2M
Oct 20, 2026$5.39$5.87$5.31$5.841.56M
Oct 19, 2026$5.51$5.69$5.37$5.37869.59K
Oct 16, 2026$5.53$5.55$5.27$5.42648.47K
Oct 15, 2026$5.35$5.59$5.30$5.53867.83K
Oct 14, 2026$5.32$5.52$5.1925$5.331.2M
Oct 13, 2026$6.06$6.09$5.47$5.491.58M
Oct 12, 2026$6.09$6.21$5.85$6.091.02M
Oct 9, 2026$5.65$6.02$5.54$5.971.05M
Oct 8, 2026$5.56$5.885$5.42$5.662.49M
Oct 7, 2026$5.76$5.825$5.552$5.6551.11M
Oct 6, 2026$6.55$6.65$5.85$5.861.6M
Oct 5, 2026$6.73$6.85$6.295$6.501.24M

Latest STTK news

The latest Smart Investors Daily articles mentioning STTK.

Stock researchCompany · Overview

STTK research

Overview

Company profile and research snapshot.

Company profile

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$4.00
Implied upside
—
Analysts
12
STTK recent ratings
DateFirmRatingTarget
Oct 12, 2026UBSBuy—
Oct 2, 2026WedbushOutperform—
Oct 2, 2026NeedhamBuy—
Aug 24, 2026Raymond JamesStrong Buy—
Aug 11, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 13, 2026

Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced two upcoming poster presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17–20, 2026, in Barcelona,

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By